Reshape Biotech

reshapebiotech.com →

+49%

est. 2Y upside i

HealthcareSeries A

Robots that automate the everyday tasks of microbiologists.

Rank

#1721

Sector

Biotech & Lab Automation

Est. Liquidity

~6Y

Data Quality

Data: Low

Reshape Biotech is a high-risk equity situation that requires caution.

Last updated: May 14, 2026

Bull (15%)+300%

Reshape re-accelerates to 40%+ YoY revenue growth by 2027 through pharma and agri-biotech expansion, raising a Series B at ~$150-200M valuation; a strategic acquirer (Danaher, Thermo Fisher) or IPO by 2031-2032 at $500M+ yields ~300% upside from the estimated ~$70M post-Series A valuation, net of 1-2 additional dilutive rounds.

Base (50%)+60%

Revenue recovers to 15-20% YoY growth, supporting a Series B at $100-130M in 2027; eventual exit at $180-250M by 2031-2033 yields roughly 60% upside for common shareholders after absorbing the $29.2M preference stack, future dilution, and expanded option pools.

Bear (35%)-75%

2.7% YoY growth in 2025-2026 signals stalled product-market fit or execution failure post-Series A; a down round, bridge note, or acqui-hire at $30-50M leaves $29.2M in liquidation preferences consuming virtually all proceeds, with common stock holders recovering near zero (-75% to -90%).

Est. time to liquidity~6.0 years

Preference Stack Risk

severe

Funding Intensity

42%

$29.2M in total liquidation preferences against an estimated ~$70M post-money Series A valuation implies approximately 42% of exit proceeds are absorbed by preferred shareholders before common stock participates.

Dilution Risk

high

A Series A company requiring 6+ years to liquidity will almost certainly raise 2-3 additional rounds, diluting common stock by an estimated additional 30-50% on top of current grant size.

Secondary Liquidity

none

No secondary market signals exist for a Denmark-based Series A lab-automation company at this scale; equity will be entirely illiquid until a public offering or M&A event.

Other — 1 role

View all 1 open roles at Reshape Biotech →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Reshape Biotech's data — designed to show you've done your homework.

  • 1

    “Revenue grew only 2.7% YoY to $13.2M — what is the root cause of the growth slowdown, what specific initiatives are in place to re-accelerate, and what does the current pipeline and close rate look like heading into H2 2026?”

  • 2

    “What is the current revenue split between one-time hardware/instrument sales and recurring software/AI subscription ARR, and what are the gross margins on each stream — specifically, is the RaaS model already generating positive unit economics?”

  • 3

    “What is the company's current post-money valuation and fully diluted share count, how large is the option pool as a percent of fully diluted shares, and what is the board's expected timeline and preferred path to a liquidity event?”

Community

Valuation Sentiment

Our model estimates +49% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.